Skip to content
10-Q

Quarterly Report

Kiniksa Pharmaceuticals International, plc KNSA

0001104659-26-050359

← back to feed
Filed
Apr 28, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 82.41M sh
Shares Diluted Q1 2026 · Mar 31, 2025 76.15M sh
Capex Q1 2026 · Mar 31, 2026 $161K
Capex Q1 2026 · Mar 31, 2025 $99K
Operating Cash Flow Q1 2026 · Mar 31, 2026 $50.2M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $22.32M
Short Term Investments Q1 2026 · Mar 31, 2026 $278.14M
Short Term Investments Q1 2026 · Dec 31, 2025 $248.48M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $189.95M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $165.6M
Stockholders Equity Q1 2026 · Mar 31, 2026 $605.69M
Stockholders Equity Q1 2026 · Dec 31, 2025 $567.61M
Stockholders Equity Q1 2026 · Mar 31, 2025 $457.49M
Stockholders Equity Q1 2026 · Dec 31, 2024 $438.44M
Current Liabilities Q1 2026 · Mar 31, 2026 $156.61M
Current Liabilities Q1 2026 · Dec 31, 2025 $139.18M
Total Liabilities Q1 2026 · Mar 31, 2026 $219.59M
Total Liabilities Q1 2026 · Dec 31, 2025 $196.03M
Current Assets Q1 2026 · Mar 31, 2026 $594.17M
Current Assets Q1 2026 · Dec 31, 2025 $527.18M
Total Assets Q1 2026 · Mar 31, 2026 $825.28M
Total Assets Q1 2026 · Dec 31, 2025 $763.63M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.27
Eps Diluted Q1 2026 · Mar 31, 2025 $0.11
Eps Basic Q1 2026 · Mar 31, 2026 $0.30
Eps Basic Q1 2026 · Mar 31, 2025 $0.12
Sga Expense Q1 2026 · Mar 31, 2026 $61.15M
Sga Expense Q1 2026 · Mar 31, 2025 $43.53M
Rd Expense Q1 2026 · Mar 31, 2026 $27.48M
Rd Expense Q1 2026 · Mar 31, 2025 $19.33M
Net Income Q1 2026 · Mar 31, 2026 $22.59M
Net Income Q1 2026 · Mar 31, 2025 $8.54M
Operating Income Q1 2026 · Mar 31, 2026 $29.27M
Operating Income Q1 2026 · Mar 31, 2025 $13.27M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $20.8M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $17.87M
Revenue Q1 2026 · Mar 31, 2026 $214.27M
Revenue Q1 2026 · Mar 31, 2025 $137.79M